TY - JOUR
T1 - Expression of uPAR mRNA in peripheral blood is a favourite marker for metastasis in gastric cancer cases
AU - Kita, Y.
AU - Fukagawa, T.
AU - Mimori, K.
AU - Kosaka, Y.
AU - Ishikawa, K.
AU - Aikou, T.
AU - Natsugoe, S.
AU - Sasako, M.
AU - Mori, M.
N1 - Funding Information:
This work was supported by the following grant sponsors: CREST, Japan Science and Technology Agency (JST); Japan Society for the
Funding Information:
Promotion of Science (JSPS) Grant-in-Aid for Scientific Research, Grant numbers 17109013, 17591411, 17591413, 18390367, 18590333, 18659384 and 18790964; The Ministry of Education, Culture, Sports,
PY - 2009/1/13
Y1 - 2009/1/13
N2 - Urokinase-type plasminogen activator receptor (uPAR) plays a central role in the plasminogen activation cascade and participates in extracellular matrix degradation, cell migration and invasion. We evaluated the expression level of uPAR mRNA and the presence of isolated tumour cells (ITCs) in bone marrow (BM) and peripheral blood (PB) in gastric cancer patients and clarified its clinical significance. We assessed specific uPAR mRNA expression by quantitative real-time reverse transcriptase- polymerase chain reaction (RT-PCR) in BM and PB in 846 gastric cancer patients as well as three epithelial cell markers, carcinoembryonic antigen (CEA), cytokeratin (CK)-19 and CK-7. The uPAR mRNA expression in bone marrow and peripheral blood expressed significantly higher than normal controls (P<0.0001). The uPAR mRNA in BM showed concordant expression with the depth of tumour invasion, distant metastasis, and the postoperative recurrence (P=0.015, 0.044 and 0.010, respectively); whereas in PB, we observed more intimate significant association between uPAR expression and clinicopathologic variables, such as depth of tumour invasion, the distant metastasis, the venous invasion and the clinical stage (P=0.009, 0.002, 0.039 and 0.008, respectively). In addition, the uPAR mRNA expression in PB was an independent prognostic factor for distant metastasis by multivariate analysis. We disclosed that it was possible to identify high-risk patients for distant metastasis by measuring uPAR mRNA especially in peripheral blood at the timing of operation in gastric cancer patients.
AB - Urokinase-type plasminogen activator receptor (uPAR) plays a central role in the plasminogen activation cascade and participates in extracellular matrix degradation, cell migration and invasion. We evaluated the expression level of uPAR mRNA and the presence of isolated tumour cells (ITCs) in bone marrow (BM) and peripheral blood (PB) in gastric cancer patients and clarified its clinical significance. We assessed specific uPAR mRNA expression by quantitative real-time reverse transcriptase- polymerase chain reaction (RT-PCR) in BM and PB in 846 gastric cancer patients as well as three epithelial cell markers, carcinoembryonic antigen (CEA), cytokeratin (CK)-19 and CK-7. The uPAR mRNA expression in bone marrow and peripheral blood expressed significantly higher than normal controls (P<0.0001). The uPAR mRNA in BM showed concordant expression with the depth of tumour invasion, distant metastasis, and the postoperative recurrence (P=0.015, 0.044 and 0.010, respectively); whereas in PB, we observed more intimate significant association between uPAR expression and clinicopathologic variables, such as depth of tumour invasion, the distant metastasis, the venous invasion and the clinical stage (P=0.009, 0.002, 0.039 and 0.008, respectively). In addition, the uPAR mRNA expression in PB was an independent prognostic factor for distant metastasis by multivariate analysis. We disclosed that it was possible to identify high-risk patients for distant metastasis by measuring uPAR mRNA especially in peripheral blood at the timing of operation in gastric cancer patients.
UR - http://www.scopus.com/inward/record.url?scp=58149231216&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58149231216&partnerID=8YFLogxK
U2 - 10.1038/sj.bjc.6604806
DO - 10.1038/sj.bjc.6604806
M3 - Article
C2 - 19050704
AN - SCOPUS:58149231216
SN - 0007-0920
VL - 100
SP - 153
EP - 159
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 1
ER -